Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Novel selective and orally active inhibitors of PKB show potent antitumor effects in vivo

Feb. 17, 2010

FDA approves REMS for erythropoiesis-stimulating agents

Feb. 17, 2010

U.K. MHRA approves Oncolytics' phase III trial of Reolysin in head and neck cancers

Feb. 17, 2010

Tyrosine kinase inhibitors for cancer therapy disclosed by Merck KGaA

Feb. 17, 2010

TopoTarget discloses novel NMPRTase inhibitors

Feb. 17, 2010

Genentech identifies new Janus kinase inhibitors

Feb. 16, 2010

Millennium Pharmaceuticals patents novel proteasome inhibitors

Feb. 16, 2010

Debiopharm's Clinical Trial Application for Debio-0932 approved in France

Feb. 16, 2010

Oxigene presents update on development of Zybrestat

Feb. 16, 2010

YM BioSciences presents CYT-387 and CYT-997 data

Feb. 15, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...